Treatment with Rapa-SLE-EV also significantly reduced the plasma levels of BAFF, IL-17A, IL-12p70, IL-4, IL-5, GM-CSF, and CXCL2. This evidence concerns the gene CXCL2 and systemic lupus erythematosus.